| Unique ID issued by UMIN | UMIN000057842 |
|---|---|
| Receipt number | R000066014 |
| Scientific Title | Tranexamic Acid in Patients with Traumatic Hemorrhagic Shock: A Systematic Review and Meta-analysis |
| Date of disclosure of the study information | 2025/05/12 |
| Last modified on | 2026/11/11 11:31:30 |
Tranexamic Acid in Patients with Traumatic Hemorrhagic Shock: A Systematic Review and Meta-analysis
Tranexamic Acid in Patients with Traumatic Hemorrhagic Shock: A Systematic Review and Meta-analysis
Tranexamic Acid in Patients with Traumatic Hemorrhagic Shock: A Systematic Review and Meta-analysis
Tranexamic Acid in Patients with Traumatic Hemorrhagic Shock: A Systematic Review and Meta-analysis
| Japan |
Traumatic Hemorrhagic Shock Patients
| Emergency medicine |
Others
NO
To assess the Efficacy and Safety of Tranexamic Acid in Traumatic Hemorrhagic Shock Patients
Efficacy
Functional Outcome
Adverse Event
Total Blood Product Usage
ICU Length of Stay
Hospital Length of Stay
Short-term Mortality
Long-term Mortality
Others,meta-analysis etc
| 18 | years-old | <= |
| Not applicable |
Male and Female
Randomized controlled trial including more than 50% of patients with traumatic hemorrhagic shock
Conference abstract
Language other than English
| 1st name | Nobuto |
| Middle name | |
| Last name | Nakanishi |
Kobe University Graduate School of Medicine
Division of Disaster and Emergency Medicine, Department of Surgery Related
650-0017
7-5-2 Kusunoki, Chuo-ward, Kobe, 650-0017, Japan
0783826521
nobuto_nakanishi@yahoo.co.jp
| 1st name | Nobuto |
| Middle name | |
| Last name | Nakanishi |
Kobe University Graduate School of Medicine
Division of Disaster and Emergency Medicine, Department of Surgery Related
650-0017
7-5-2 Kusunoki, Chuo-ward, Kobe, 650-0017, Japan
0783826521
nobuto_nakanishi@yahoo.co.jp
Kobe university
The Japanese Association for the Surgery of Trauma
Other
Kobe University Graduate School of Medicine
7-5-2 Kusunoki, Chuo-ward, Kobe, 650-0017, Japan
078-382-6521
nobuto_nakanishi@yahoo.co.jp
NO
兵庫県
| 2025 | Year | 05 | Month | 12 | Day |
https://www.dropbox.com/scl/fi/icvxruarrz324b0606hil/3_protcol_link-to-umine_20250514.pdf?rlkey=quxq
Unpublished
None
22516
Favorable functional outcomes did not differ between the TXA and control groups (RR 1.01, 95% CI 0.99-1.03; 2 trials, n=21,258). TXA reduced short-term mortality (RR 0.89, 95% CI 0.82-0.96). Hospital stay was shorter with TXA (mean difference -1.13 days), but this exploratory finding was based on only 2 studies (n=188). No significant differences were found in adverse events, blood product use, or long-term mortality.
| 2026 | Year | 10 | Month | 26 | Day |
Adult patients with traumatic hemorrhagic shock. Traumatic hemorrhagic shock was defined as traumatic hemorrhage accompanied by hemodynamic instability according to the prespecified eligibility criteria of each included study. As the definitions of hemodynamic instability differed across trials, no uniform post hoc threshold was applied. Studies were included when the study population was explicitly described as having hemorrhagic shock or when more than or equal to 50% of patients were judged by to have hemorrhagic shock.
An extensive search of three databases yielded a total of 2,166 records. Of these, 301 duplicate records were removed, leaving 1865 records for title and abstract screening. Based on the eligibility criteria, 1,833 records were excluded following title and abstract screening, and 32 reports were sought for retrieval. One report could not be retrieved. Therefore, 31 full-text reports were assessed for eligibility. Ultimately, five RCTs (22516 patients) were included in this systematic review and meta-analysis.
All adverse events were included in the analysis; five studies encompassing 22,516 patients assessed adverse events . TXA did not increase the occurrence of adverse events (RR, 0.82; 95% CI, 0.55 to 1.22; very low CoE). Owing to the overall high risk of bias in one study, certainty in risk of bias was downgraded one level. Imprecision was considered serious because the CI spanned two zones. Considering the study size and the pattern of effect estimates across studies, publication bias was considered serious, causing the overall CoE to be downgraded to very low certainty.
The primary outcome was (1) favorable functional outcome, based on each study's criteria. The secondary outcomes encompassed (2) adverse events; (3) total blood product usage; (4) length of ICU (intensive care unit) stay; (5) hospital length of stay; (6) short-term mortality (30-day or in-hospital mortality); and (7) long-term mortality.
Completed
| 2025 | Year | 05 | Month | 12 | Day |
| 2025 | Year | 05 | Month | 12 | Day |
| 2025 | Year | 05 | Month | 12 | Day |
| 2025 | Year | 05 | Month | 12 | Day |
| 2025 | Year | 11 | Month | 11 | Day |
This study is a systematic review and meta-analysis; therefore, no patient enrollment is required.
Subgroup analyses will be performed based on the following factors: (1) timing of tranexamic acid administration, (2) dosage of tranexamic acid, and (3) site of trauma.
| 2025 | Year | 05 | Month | 12 | Day |
| 2026 | Year | 11 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066014